Display options
Cite
Wang Z, Xu X, Tan Q, et al. Treatment of major depressive disorders with generic duloxetine and paroxetine: a multi-centered, double-blind, double-dummy, randomized controlled clinical trial. Shanghai Arch Psychiatry. 2015;27(4):228-36doi: 10.11919/j.issn.1002-0829.215064.
Wang, Z., Xu, X., Tan, Q., Li, K., Ma, C., Xie, S., Gao, C., Wang, G., & Li, H. (2015). Treatment of major depressive disorders with generic duloxetine and paroxetine: a multi-centered, double-blind, double-dummy, randomized controlled clinical trial. Shanghai archives of psychiatry, 27(4), 228-36. https://doi.org/10.11919/j.issn.1002-0829.215064
Wang, Zhiyang, et al. "Treatment of major depressive disorders with generic duloxetine and paroxetine: a multi-centered, double-blind, double-dummy, randomized controlled clinical trial." Shanghai archives of psychiatry vol. 27,4 (2015): 228-36. doi: https://doi.org/10.11919/j.issn.1002-0829.215064
Wang Z, Xu X, Tan Q, Li K, Ma C, Xie S, Gao C, Wang G, Li H. Treatment of major depressive disorders with generic duloxetine and paroxetine: a multi-centered, double-blind, double-dummy, randomized controlled clinical trial. Shanghai Arch Psychiatry. 2015 Aug 25;27(4):228-36. doi: 10.11919/j.issn.1002-0829.215064. PMID: 26549959; PMCID: PMC4621288.
Copy Download .nbib Format: NLM
Share it on

Shanghai Arch Psychiatry. 2015 Aug 25;27(4):228-36. doi: 10.11919/j.issn.1002-0829.215064.

Treatment of major depressive disorders with generic duloxetine and paroxetine: a multi-centered, double-blind, double-dummy, randomized controlled clinical trial.

Shanghai archives of psychiatry

Zhiyang Wang, Xiufeng Xu, Qingrong Tan, Keqing Li, Cui Ma, Shiping Xie, Chengge Gao, Gang Wang, Huafang Li

Affiliations

  1. Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China ; Department of Psychiatry, Huashan Hospital, Fudan University, Shanghai, China.
  2. Department of Psychiatry, First Affiliated Hospital, Kunming Medical College, Kunming, Yunnan Province, China.
  3. Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi Province, China.
  4. Hebei Mental Health Center, Baoding, Hebei Province, China.
  5. Guangzhou Brain Hospital, Guangzhou, Guangdong Province, China.
  6. Affiliated Brain Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China.
  7. First Affiliated Hospital of Xi'an, Jiao Tong University Medical College, Xi'an, Shaanxi Province, China.
  8. Beijing Anding Hospital, Capital Medical University, Beijing, China.
  9. Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

PMID: 26549959 PMCID: PMC4621288 DOI: 10.11919/j.issn.1002-0829.215064

Abstract

BACKGROUND: This study is a pre-registration trial of generic duloxetine that was approved by the China Food and Drug Administration (approval number: 2006L01603).

AIMS: Compare the treatment efficacy and safety of generic duloxetine to that of paroxetine in patients with major depressive disorders (MDD).

METHODS: This was a double-dummy, double-blind, multicenter, positive drug (paroxetine), parallel randomized controlled clinical trial. The 299 patients with MDD recruited for the study were randomly assigned to use duloxetine (n=149; 40-60 mg/d) or paroxetine (n=150; 20 mg/d) for 8 weeks. The Hamilton Depression rating scale (HAMD-17) was administered at baseline and 1, 2, 4, 6, and 8 weeks after starting treatment. Remission was defined as a HAMD-17 score below 8 at the end of the trial, and treatment effectiveness was defined as a decrease in baseline HAMD-17 score of at least 50% by the end of the trial. Safety was assessed based on the reported prevalence and severity of side effects and changes in laboratory and electrocardiographic findings. Three patients in the duloxetine group dropped out before starting medication, so results were analyzed using a modified intention-to-treat (ITT) method with 146 in the experimental group and 150 in the control group.

RESULTS: Both groups experienced 29 dropouts during the 8-week trial. HAMD-17 scores decreased significantly from baseline throughout the trial in both groups. Based on the ITT analysis, at the end of the trial there was no significant difference between the duloxetine group and the paroxetine group in effectiveness (67.1% v. 71.3%, X(2)=0.62 p=0.433), remission rate (41.1% v. 51.3%, X(2)=3.12, p=0.077), or in the incidence of side effects (56.8% v. 54.7%, X(2)=0.14, p=0.705).

CONCLUSIONS: Generic duloxetine is as effective and safe as paroxetine in the acute treatment of patients with MDD who seek care at psychiatric outpatient departments in China.

Keywords: China; duloxetine; efficacy; major depressive disorder; paroxetine; randomized controlled trial; safety

References

  1. J Clin Psychiatry. 2001;62 Suppl 8:4-9; discussion 10-1 - PubMed
  2. Lancet. 2009 Jun 13;373(9680):2041-53 - PubMed
  3. Pharmacotherapy. 2005 Mar;25(3):396-410 - PubMed
  4. Am J Health Syst Pharm. 2005 Dec 1;62(23):2481-90 - PubMed
  5. Int Clin Psychopharmacol. 2012 Jan;27(1):17-26 - PubMed
  6. Am J Psychiatry. 2007 Feb;164(2):201-4 - PubMed
  7. Expert Rev Neurother. 2009 Feb;9(2):155-65 - PubMed
  8. Clin J Pain. 2012 Nov-Dec;28(9):775-81 - PubMed
  9. Curr Med Res Opin. 2011 Oct;27(10):1849-58 - PubMed
  10. Psychiatry Clin Neurosci. 2007 Jun;61(3):295-307 - PubMed
  11. J Clin Psychiatry. 2012;73 Suppl 1:5-9 - PubMed
  12. CNS Drugs. 2009;23(6):523-41 - PubMed
  13. Lancet. 2013 Nov 9;382(9904):1575-86 - PubMed
  14. Ann Gen Psychiatry. 2007 Sep 05;6:23 - PubMed
  15. J Clin Psychopharmacol. 2004 Aug;24(4):389-99 - PubMed
  16. Drugs Context. 2013 Jan 03;2013:212245 - PubMed
  17. Drug Saf. 2010 May 1;33(5):393-407 - PubMed
  18. J Clin Psychopharmacol. 2007 Dec;27(6):672-6 - PubMed
  19. J Clin Psychiatry. 2002 Apr;63(4):308-15 - PubMed

Publication Types